Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Irinotecan (also known as CPT-11; Camptosar; Irinophore C; CPT11; Irinotecan lactone; Irinotecanum), a semisynthetic analog of camptothecin and the prodrug of 7-ethyl-10-hydroxy-camptothecin (SN-38), is a topoisomerase I inhibitor approved for use as an anticancer drug. In LoVo and HT-29 cells, it inhibits topoisomerase I with IC50 values of 15.8 μM and 5.17 μM, respectively.
Targets |
Topoisomerase I
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
In 20 cm2 dishes, exponentially growing cells are seeded with the ideal number of cells for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They receive treatment with irinotecan or SN-38 at increasing concentrations for a single cell doubling period (24 hours for LoVo cells and 40 hours for HT-29 cells) after two days. Following a 0.15 M NaCl wash, the cells are cultured in normal medium for two more doubling times before being separated from the support using trypsin-EDTA and counted using a hemocytometer. Subsequently, the drug concentrations that cause a 50% inhibition of growth in cells treated with the drug are estimated as the IC50 values[2].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C33H38N4O6
|
|
---|---|---|
Molecular Weight |
586.68
|
|
Exact Mass |
586.28
|
|
Elemental Analysis |
C, 67.56; H, 6.53; N, 9.55; O, 16.36
|
|
CAS # |
97682-44-5
|
|
Related CAS # |
100286-90-6;136572-09-3
|
|
Appearance |
Solid powder
|
|
SMILES |
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
|
|
InChi Key |
UWKQSNNFCGGAFS-XIFFEERXSA-N
|
|
InChi Code |
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
|
|
Chemical Name |
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% Propylene glycol , 5% Tween 80 , 65% D5W: 30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7045 mL | 8.5225 mL | 17.0451 mL | |
5 mM | 0.3409 mL | 1.7045 mL | 3.4090 mL | |
10 mM | 0.1705 mL | 0.8523 mL | 1.7045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02631733 | Active Recruiting |
Drug: Irinotecan Sucrosofate Drug: Ferumoxytol |
Malignant Solid Neoplasm | National Cancer Institute (NCI) |
May 31, 2017 | Phase 1 |
NCT03263429 | Active Recruiting |
Drug: Irinotecan Hydrochloride (phase I only) Biological: Panitumumab |
Colorectal Cancer Metastatic Colorectal Cancer |
Vanderbilt-Ingram Cancer Center | August 23, 2017 | Phase 1 Phase 2 |
NCT04641871 | Active Recruiting |
Drug: Irinotecan Drug: Pevonedistat |
Recurrent Lymphoma Refractory Lymphoma |
Children's Oncology Group | January 11, 2018 | Phase 1 |
NCT03323034 | Active Recruiting |
Drug: Irinotecan Hydrochloride Biological: Dinutuximab |
High Risk Neuroblastoma Recurrent Neuroblastoma |
Children's Oncology Group | July 8, 2019 | Phase 2 |
NCT03567629 | Active Recruiting |
Drug: Irinotecan Drug: Oxaliplatin |
mCRC | Peking University | May 29, 2018 | Phase 2 |
Genome Med . 2016 Oct 31;8(1):116. td> |